Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Cytokinetics Inc (CYTK)  
$48.30 0.68 (1.39%) as of 4:30 Fri 5/24


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 122,563,000
Market Cap: 5.92(B)
Last Volume: 8,264,325 Avg Vol: 8,241,683
52 Week Range: $26.88 - $108.06
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 91,318 237,059 410,079 888,401
Total Sell Value $6,319,460 $16,812,843 $22,688,654 $44,103,545
Total People Sold 2 4 5 11
Total Sell Transactions 4 16 36 82
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 718
  Page 1 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Parshall B Lynne Director   •       •      –    2024-05-15 4 A $0.00 $0 D/D 5,600 20,600     -
   Bhanji Muna Director   •       •      –    2024-05-15 4 A $0.00 $0 D/D 5,600 19,631     -
   Kaye Edward M. Md Director   •       •      –    2024-05-15 4 A $0.00 $0 D/D 5,600 24,917     -
   Wierenga Wendall D Director   •       •      –    2024-05-15 4 A $0.00 $0 D/D 5,600 24,327     -
   Costa Santo J Director   •       •      –    2024-05-15 4 A $0.00 $0 D/D 5,600 20,600     -
   Henderson John T Director   •       •      –    2024-05-15 4 A $0.00 $0 D/D 5,600 37,670     -
   Wysenski Nancy Director   •       •      –    2024-05-15 4 A $0.00 $0 D/D 5,600 22,756     -
   Harrington Robert Arthur Director   •       •      –    2024-05-15 4 A $0.00 $0 D/D 5,600 17,121     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-05-07 4 AS $65.11 $1,012,265 D/D (15,547) 137,056 -26%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-05-07 4 OE $6.67 $94,621 D/D 14,186 152,603     -
   Henderson John T Director   •       •      –    2024-04-25 4 AS $64.54 $681,671 D/D (10,562) 32,070 -25%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-04-12 4 GD $0.00 $0 D/D 150 138,417     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-04-09 4 S $74.31 $2,422,918 D/D (32,605) 138,567 36%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-04-09 4 OE $6.67 $190,795 D/D 28,605 171,172     -
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2024-03-14 4 A $0.00 $0 D/D 16,941 63,887     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-14 4 A $0.00 $0 D/D 21,333 142,567     -
   Wong Robert VP, Chief Accounting Officer   •       •      –    2024-03-14 4 A $0.00 $0 D/D 4,079 29,664     -
   Blum Robert I President & CEO   •       •      –    2024-03-14 4 A $0.00 $0 D/D 61,490 461,221     -
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2024-03-06 4 D $66.88 $341,289 D/D (5,103) 46,946     -
   Wong Robert VP, Chief Accounting Officer   •       •      –    2024-03-06 4 D $66.88 $57,316 D/D (857) 25,585     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-06 4 D $66.88 $542,330 D/D (8,109) 121,234     -
   Blum Robert I President & CEO   •       •      –    2024-03-06 4 D $66.88 $1,118,568 D/D (16,725) 399,731     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-05 4 AS $67.53 $2,202,606 D/D (32,604) 138,973 -27%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2024-03-05 4 OE $6.67 $190,789 D/D 28,604 167,577     -
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2024-03-04 4 D $67.68 $149,031 D/D (2,202) 52,049     -

  718 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed